By conventional laboratory evaluation procedures, the in vitro antibacterial activities of cefamandole and its O-formyl ester, cefamandole nafate, appear virtually identical. When the activities of these two compounds were exaniined for their ability to lyse log-phase cultures of susceptible bacteria, however, cefamandole was found to be about 10 times more active than cefamandole nafate. Cefamandole nafate was shown to be rapidly converted to cefamandole in bacteriological media, with a half-life of less than 1 h at a pH of 7.0 or above. At pH 6.0, in log-phase inhibition experiments, however, cefamandole nafate is more stable, allowing delineation of the activity between cefamandole and cefamandole nafate. The efficacy of cefamandole was identical to that of cefamandole nafate in treating experimental animal infections, indicating that rapid conversion of cefamandole nafate to cefamandole occurs in vivo.
The antibacterial activity of cefamandole, 7- n-mandelamido-3f[(1-methyl-1H-tetrazol-5-yl)-thio]methyl}3-cephem-4-carboxylic acid, was first described by Wick and Preston (7), who showed that this antibiotic has very good activity against gram-negative bacteria, including ,8-lactamase-producing strains of Proteus and
Enterobacter. Subsequently, this antibiotic was introduced into clinical trial as the sodium salt of the O-formyl ester of cefamandole and designated as cefamandole nafate. This derivative, which is stable in the crystalline form, is rapidly converted to cefamandole by hydrolysis of the formyl ester in vitro after dissolution. Because ofrapid in vivo conversion of cefamandole nafate to cefamandole (4), the latter is the predominant circulating antibiotic after administration of cefamandole nafate to laboratory animals or humans (J. S. Wold, R. R. Joost, H. R. Black, and K. E. Briscoe, Ninth International Congr. Chemother., M225, 1975) .
The in vitro antibiotic activity of cefamandole nafate was shown (R. B. Kammer, D. A. Preston, and J. R. Turner, Ninth International Congr. Chemother., M226, 1975) to be equivalent to cefamandole lithium by conventional agar dilution and disk plate susceptibility tests against a number ofbacterial pathogens. It was also reported that a differential in activity between these two antibiotics was detectable against Bacillus subtilis based on a decreased growth rate in log-phase cultures, although only at concentrations below 0.1 ,ug/ml. We have shown that these apparently contradictory findings are the result of two basic differences in experimental conditions between the two tests: the duration of the experiments and the pH at which these experiments were performed. Staphylococcus aureus, Escherichia coli, and Klebsiella pneumoniae were grown for 18 h at 36°C on Trypticase soy agar (BBL) slants. The surface growth was suspended in saline to a density of 109 colony-forming units/ml and diluted to predetermined infective concentrations. The final dilution of these latter cultures was made in sterile 5% hog gastric mucin at pH 7.4. As with the streptococci, these bacterial suspensions were administered by intraperitoneal injection in 0.5-ml volumes.
MATERIALS AND METHODS
Groups of eight infected mice were treated subcutaneously with antibiotic (0.25-ml volumes) at 1 and 5 h after infection. Survivors and deaths were recorded daily for 7 days. The amount of antibiotic required to protect 50% of the infected mice (ED50) was estimated by the method of Reed and Muench (6) .
RESULTS
Comparison of the in vitro activity of cefamandole nafate with that of cefamandole as determined by agar dilution MIC, led to the conclusion that there was little, if any, activity difference between the two forms of cefamandole. Table 1 shows the geometric mean MICs for various genera. The MIC ofboth compounds was the same for 36 of the 51 bacterial isolates tested. There was one dilution difference in favor of cefamandole nafate with 13 isolates, and a one-dilution difference in favor of cefamandole lithium with 2 isolates. Similar results were obtained with the Food and Drug Administration standarized disk susceptibility test (2) . Zone sizes, with 30-jg disks of the two compounds, against 18 isolates representing the same groups as shown in Table 1 were almost identical.
Studies of the base-catalyzed hydrolysis of cefamandole nafate to cefamandole (4) have shown that the ester is quite unstable at pH values above 7.0. A dose-response disk susceptibility test of the two compounds against susceptible organisms on medium adjusted to pH 6.0 or 8.0, however, did not detect any difference between the two compounds, suggesting that in these media the ester is rapidly converted to cefamandole even at pH 6.0 (Fig. 1) . This notion was confirmed by assay of cefamandole and cefamandole nafate in uninoculated medium incubated for the same time periods and temperatures as the cultures ( three cultures, i.e., about 7 ,ug/ml. This amount of cefamandole alone was not sufficient to cause lysis of strain EC-14 (Fig. 4) , suggesting that the activity ascribed to cefamandole nafate in this experiment is a combination of the accu- mulated cefamandole plus the remaining cefamandole nafate.
The contribution of cefamandole nafate to the observed activity in a mixture of cefamandole nafate and cefamandole was calculated using the half-life of cefamandole nafate in this medium and the amount of cefamandole required to cause lysis at a given time. For example, 100 ,ug of cefamandole nafate per ml caused lysis in 30 min, at which time there would have been 6.89 ug of cefamandole and 93.11 ,u of cefamandole nafate per ml in the medium. From Fig. 4 , it can be determined that 6.89 ,ug of cefamandole per ml would theoretically produce lysis in 121 min and that 16.6 ,ug/ml would be required to produce lysis in 30 min. The additional amount of cefamandole required to reduce lysis time from 121 to 30 min is, therefore, 16.6 -6.89, which equals 9.71 ,ug/ml. If one equates this calculated additional amount of cefamandole with the cefamandole nafate activity, the ratio 93.11 to 9.71 = 9.58 indicates the relative activity of the two compounds. Table 3 shows such calculations for E. coli strains EC-39 and EC-14 and B. subtilis ATCC 6633 at various concentrations of cefamandole nafate. The relative activity of cefamandole nafate deternined in this way varied from an average of 8.75 for EC-14 to 11.7 for ATCC 6633. The overall average for the three strains was 10. The activity of cefamandole is therefore about 10 times greater than that of cefamandole nafate.
As suggested from pharmacokinetic studies (Wold et al., Ninth International Congr. Chemother., M225, 1975) hydrolysis of the ester to cefamandole is sufficiently rapid to ensure that cefamandole is the predominant circulating form after the administration of cefamandole nafate. This would predict that the two compounds should show equal efficacy in treatment of experimental animal infections, in spite of the lower in vitro activity of cefamandole nafate. M225, 1975) . This is confirmed by the data presented here;
i.e., animal infections show the same response after treatment with either cefamandole or cefamandole nafate. In addition, cefamandole nafate, in powder form or on a paper disk, is vulnerable to hydrolysis from moisture in the air, resulting in conversion to amorphous cefamandole. The amorphous form of cefamandole is relatively susceptible to degradation (5) . Cefamandole lithium, however, is quite stable in preparations used for experimental purposes and laboratory standards and has been used to prepare disks for susceptibility tests. It is clear that, although there is a difference in activity between the two compounds when examined under special conditions, cefamandole lithium is a suitable form to assess the susceptibility of bacteria to the pharmaceutical preparation, which is cefamandole nafate.
